Abeona Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its participation in key investor conferences in September 2020. CEO João Siffert will engage in virtual one-on-one meetings at Citi’s 15th Annual BioPharma Virtual Conference on September 9. Additionally, he will present at the Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET, with a live webcast available on Abeona’s website. Abeona focuses on gene and cell therapies for serious diseases, including programs for recessive dystrophic epidermolysis bullosa and Sanfilippo syndrome.

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participate in the following upcoming investor conferences.

• João Siffert, M.D., Chief Executive Officer, will conduct virtual one-on-one meetings with institutional investors at Citi’s 15^th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020.
  
  
• Dr. Siffert will present at the Wells Fargo Virtual Healthcare Conference on Thursday, September 10, 2020 at 10:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replay will be available within 24 hours of the live presentation and will be accessible for 30 days.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-201 for CLN3 disease. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Greg Gin
VP, Investor Relations
Abeona Therapeutics
+1 (646) 813-4709
ggin@abeonatherapeutics.com

Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics
+1 (718) 344-5843
ssantiamo@abeonatherapeutics.com

FAQ

What conferences will Abeona Therapeutics participate in September 2020?

Abeona Therapeutics will participate in Citi’s 15th Annual BioPharma Virtual Conference on September 9 and the Wells Fargo Virtual Healthcare Conference on September 10, 2020.

Who is presenting for Abeona Therapeutics at the investor conferences?

CEO João Siffert will present for Abeona Therapeutics at the upcoming investor conferences.

When is the Wells Fargo Virtual Healthcare Conference where Abeona will present?

The Wells Fargo Virtual Healthcare Conference is scheduled for September 10, 2020, at 10:00 a.m. ET.

How can investors access the presentation by Abeona Therapeutics?

Investors can access the live webcast of Abeona Therapeutics' presentation on their website, with a replay available for 30 days after the event.

What is Abeona Therapeutics known for?

Abeona Therapeutics is known for developing gene and cell therapies for serious diseases, including programs for epidermolysis bullosa and Sanfilippo syndrome.